drugset / Trial / NCT06280105
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib.
Timeline
- Start
- 2024-03-31
- Primary completion
- 2026-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |